CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 139 enrolled
Drug / intervention
Omega-3 Fatty Acid Supplement +1 moredrug
Likely dose
Omega-3 Fatty Acid Supplement 1,000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04495816
NCT04495816Phase 2Completed
CompareCT.gov

COVID-19 Anosmia Study

Icahn School of Medicine at Mount Sinai·interventional·Posted Aug 3, 2020·Updated Oct 23, 2023

In Brief

A Phase 2 clinical trial evaluating Omega-3 Fatty Acid Supplement and Placebo/Control for Anosmia and Covid19. Completed, enrolled 139 participants across 1 site.

Detailed Summary

To capture the natural history of COVID-19 associated olfactory dysfunction as measured by two patient reported outcome measures (SNOT-22, QOD-NS) and a 6-week BSIT with a comparison to an intervention arm receiving daily omega-3 supplements.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnosmia, Covid19
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedAug 3, 2020
Enrollment StartJul 15, 2020
Primary CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.9 years ago

Interventions

Omega-3 Fatty Acid Supplementdrug

Participants randomized to this arm will be instructed to take two of the softgels they received per day for 6 weeks. They will receive softgels containing 1,000 mg of omega-3 fatty acid. 1000 mg of omega-3 fatty acid blend including 683 mg Eicosapentaenoic Acid and 252 mg Docosahexaenoic Acid

Placebo/Controldrug

Patients randomized to this arm will also be instructed to take two of the softgels they received per day for 6 weeks. They will receive placebo softgels that are indistinguishable from those containing fish oil.